Cognitive function in schizophrenic patients

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 11, 1996, Pages

  Tollefson, Gary D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; OLANZAPINE;

AMNESIA; ATTENTION DEFICIT DISORDER; COGNITIVE DEFECT; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; NEUROPATHOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CEREBRAL CORTEX; CLOZAPINE; COGNITION DISORDERS; DOPAMINE; GLUTAMIC ACID; HUMANS; LIMBIC SYSTEM; PIRENZEPINE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEROTONIN;

EID: 10544246084     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Kraepelin E; Robertson GM, ed; Barclay RM, trans. Dementia Praecox and Paraphrenia. Huntington, NY: Krieger; 1971
2. Keefe RSE, Mohs RC, Arnsten AST, et al. Dissecting cognitive impairment in schizophrenia: implications for treatment. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology; December 11-15, 1995; San Juan, Puerto Rico
3. Kolakowska T, Williams AO, Ardern M, et al. Schizophrenia with good and poor outcome, I: early clinical features, response to neuroleptics and signs of organic dysfunction. Br J Psychiatry 1985;146:229-246
4. Breier A, Schreiber JL, Dyer J, et al. National Institute of Mental Health Longitudinal Study of Chronic Schizophrenia. Arch Gen Psychiatry 1991; 48:239-246
5. Perlick D, Mattis S, Stastny P, et al. Neuropsychological discriminators of long-term inpatient or outpatient status in chronic schizophrenia. J Neuropsychiatry Clin Neurosci 1992;4:428-434
6. Goldberg TE, Kelsoe JR, Weinberger DR, et al. Performance of schizophrenic patients on putative neuropsychological tests of frontal lobe function. Int J Neurosci 1988;42:51-58
7. Gold JM, Harvey PD. Cognitive deficits in schizophrenia. Psychiatr Clin North Am 1993;16:295-312
8. Rappaport D, Gill M, Schafer R. Diagnostic Psychological Testing. Chicago, III: Year Book Publishers; 1945/46
9. Goldberg TE, Ragland JD, Torrey EF, et al. Neuropsychological assessment of monozygotic twins discordant for schizophrenia. Arch Gen Psychiatry 1990;47:1066-1072
10. Hull CL. The formation and retention of associations among the insane. Am J Psychol 1917;28:419-435
11. Goldberg TE, Gold JM. Neurocognitive deficits in schizophrenia. In: Hirsch SR, Weinberger DR, eds. Schizophrenia. London, England: Blackwell Science Lmtd; 1995
12. Goldberg TE, Torrey EF, Gold JM, et al. Learning and memory in monozygotic twins discordant for schizophrenia. Psychol Med 1993;23:71-85
13. Sengel RA, Lovallo WR. Effects of cueing on immediate and recent memory in schizophrenics. J Nerv Ment Dis 1983;171:426-430
14. Posner MI, Early TS, Reiman E, et al. Asymmetries in hemispheric control of attention in schizophrenia. Arch Gen Psychiatry 1988;45:814-821
15. Weinberger DR, Berman KF, Illowsky BP. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, III: a new cohort and evidence for a monoaminergic mechanism. Arch Gen Psychiatry 1988;45: 609-615
16. Shallice T. From Neuropsychology to Mental Structure. Cambridge, Mass: Cambridge University Press; 1988
17. Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 1989;98: 367-380
18. Goldberg TE, Greenberg RD, Griffin SJ, et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatr 1993;162:43-48
19. Hagger C, Buckley P, Kenny JT, et al. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993;34:702-712
20. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994;36:717-725
21. Sheitman B, Bilder R, Alvir J, et al. Cognitive ability and the time to treatment response in first episode schizophrenia. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology; December 11-15, 1995; San Juan, Puerto Rico
22. Goldberg TE, Weinberger DR. Schizophrenia, training paradigms, and the Wisconsin Card Sorting Test redux. Schizophr Res 1994;11:291-296
23. Bellack AS, Mueser KT, Morrison RL, et al. Remediation of cognitive deficits in schizophrenia. Am J Psychiatry 1990,147:1650-1655
24. Summerfelt AT, Alphs LD, Wagman AMI, et al. Reduction in perseverative errors in patients with schizophrenia using monetary feedback. J Abnorm Psychol 1991;100:613-616
25. Tompkins LM, Goldman RS, Axelrod BN. Modifiability of neuropsychological dysfunction in schizophrenia [abstract]. J Exp Clin Neuropsychol 1991;14:57
26. Green MF, Satz P, Ganzell S, et al. Wisconsin Card Sorting Test performance in schizophrenia: remediation of a stubborn deficit. Am J Psychiatry 1992;149:62-67
27. Heaton RK, Drexler M. Clinical neuropsychological findings in schizophrenia and aging. In: Miller NE, Cohen GD, eds. Schizophrenia and Aging: Schizophrenia, Paranoia and Schizophreniform. New York, NY: Guilford Press; 1987:145-161
28. Miller R. Schizophrenia as a progressive disorder: relations to EEG, CT, neuropathological and other evidence. Prog Neurobiol 1989;33:17-44
29. Walker E, Lewine RJ. Prediction of adult-onset schizophrenia from childhood home movies of the patients. Am J Psychiatry 1990;147:1052-1056
30. Offord DR, Cross LA. Adult schizophrenia with scholastic failure or low IQ in childhood: a preliminary report. Arch Gen Psychiatry 1971;24:431-436
31. Goldberg TE, Karson CN, Leleszi PJ, et al. Intellectual impairment in adolescent psychosis: a controlled psychometric study. Schizophr Res 1988;1:261-266
32. Bilder RM, Lipschutz -Broch L, Reiter G, et al. Intellectual deficits in first-episode schizophrenia: evidence for progressive deterioration. Schizophr Bull 1992;18:437-448
33. Lubin A, Gieseking CF, Williams HL. Direct measurement of cognitive deficit in schizophrenia. J Consult Psychol 1962;26:139-143
34. Klonoff H, Fibiger CH, Hutton GH. Neuropsychological patterns in chronic schizophrenia. J Nerv Ment Dis 1970;150:291-300
35. Smith A. Mental deterioration in chronic schizophrenia. J Nerv Ment Dis 1964;139:479-487
36. Chaikelson JS, Schwartzman AE. Cognitive changes with aging in schizophrenia. J Clin Psychol 1983;39:25-30
37. Hyde TM, Nawroz S, Goldberg TE, et al. Is there cognitive decline in schizophrenia? a cross-sectional study. Br J Psychiatry 1994;164:494-500
38. Goldstein G, Zubin J. Neuropsychological differences between young and old schizophrenics with and without associated neurological dysfunction. Schizophr Res 1990;3:117-126
39. Nopoulos P, Flashman L, Flaum M, et al. Stability of cognitive-functioning early in the course of schizophrenia. Schizophr Res 1994;14:29-37
40. Waddington JL, Youssef HA, Scully PJ, et al. The evolution of negative symptoms and cognitive (executive) dysfunction over the course of illness in schizophrenia. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology; December 11-15, 1995; San Juan, Puerto Rico
41. Silverman JM, Harvey PD, Powchik P, et al. Cognitive decline in elderly, hospitalized schizophrenic patients. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology; December 11-15, 1995; San Juan, Puerto Rico
42. Jonsson H, Nyman AK. Predicting long-term outcome in schizophrenia. Acta Psychiatr Scand 1991;83:342-346
43. Goldstein G. Cognitive and perceptual differences between schizophrenics and organics. Schizophr Bull 1978;4:160-185
44. Johnstone EC, Crow TJ, Frith CD, et al. Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet 1976;2:924-926
45. Weinberger DR, Torrey EF, Neophytides AN, et al. Lateral cerebral ventricular enlargement in chronic schizophrenia. Arch Gen Psychiatry 1979;36:735-739
46. Taylor MA, Abrams R. Cognitive impairment in schizophrenia. Am J Psychiatry 1984;141:196-201
47. Andreasen NC, Rezai K, Alliger R, et al. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia: assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 1992;49:943-958
48. Yurgelun-Todd DA, Watemaux CM, Cohen BM, et al. Functional magnetic resonance imaging of schizophrenic patients and comparison subjects during word production. Am J Psychiatry 1996;153:200-205
49. Carpenter WT, Lahti A, Holcomb H, et al. The deficit domain of psychopathology. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology; December 11-15, 1995; San Juan, Puerto Rico
50. Wolkin A, Arena L, Sanfilipo M, et al. Functional and structural imaging correlates of negative syndromes in schizophrenia. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology; December 11-15, 1995; San Juan, Puerto Rico
51. Liddle PF. Frontal lobe dysfunction associated with psychomotor poverty. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology; December 11-15, 1995; San Juan, Puerto Rico
52. DeLisi LE, Tew W, Shu-hong X, et al. A prospective follow-up study of brain morphology and cognition in first-episode schizophrenic patients: preliminary findings. Biol Psychiatry 1995;38:349-360
53. Gur RE, Arnold SE, Moberg PJ, et al. The dementia of schizophrenia: antemortem and postmortem studies. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology; December 11-15, 1995; San Juan, Puerto Rico
54. Arnold SE, Franz BR, Moberg PJ, et al. Molecular markers of neural injury and neurodegeneration in elderly patients with schizophrenia. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology, December 11-15, 1995; San Juan, Puerto Rico
55. Powchik P, Davidson M, Haroutunian V, et al. Neuropathological studies of severe cognitive impairment in schizophrenia. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology; December 11-15, 1995; San Juan, Puerto Rico
56. Davis KL, Powchik P, Davidson M, et al. Postmortem work with synaptic proteins. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology; December 11-15, 1995; San Juan, Puerto Rico
57. Haroutunian V, Knott PJ, Gabriel S, et al. Neurochemical correlates of psychopathology in the temporal lobe of elderly schizophrenics. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology; December 11-15, 1995, San Juan, Puerto Rico
58. Whitaker-Azmitia PM, Raio N, Taheny K, et al. Serotonin depletion during synaptogenesis causes permanent cognitive impairments and decreased synaptic density. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology; December 11-15, 1995; San Juan, Puerto Rico
59. Verma A, Moghaddam B. The role of excitatory amino acids in prefrontal cortex function as assessed by spatial delayed alternation performance in rats: modulation by dopamine. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology; December 11-15, 1995; San Juan, Puerto Rico
60. Meltzer HY, Thompson PA, Lee MA, et al. Neuropsychologic deficits in schizophrenia: relation to function and effect of antipsychotic drug-treatment. Neuropsychopharmacology 1996;14:S27-S33
61. Bakshi VP, Geyer MA. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology 1995;122:198-201
62. Farber NB, Foster J, Duhan NL, et al. Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity. Schizophr Res 1996;21: 33-37